JP2021527041A5 - - Google Patents

Info

Publication number
JP2021527041A5
JP2021527041A5 JP2020567772A JP2020567772A JP2021527041A5 JP 2021527041 A5 JP2021527041 A5 JP 2021527041A5 JP 2020567772 A JP2020567772 A JP 2020567772A JP 2020567772 A JP2020567772 A JP 2020567772A JP 2021527041 A5 JP2021527041 A5 JP 2021527041A5
Authority
JP
Japan
Prior art keywords
methyl
amino
pyrazino
isoindole
tetrahydro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020567772A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021527041A (ja
JP7374130B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2019/064323 external-priority patent/WO2019233941A1/en
Publication of JP2021527041A publication Critical patent/JP2021527041A/ja
Publication of JP2021527041A5 publication Critical patent/JP2021527041A5/ja
Application granted granted Critical
Publication of JP7374130B2 publication Critical patent/JP7374130B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020567772A 2018-06-05 2019-06-03 自己免疫疾患治療用の新規なテトラヒドロ-1H-ピラジノ[2,1-a]イソインドリルキノリン化合物 Active JP7374130B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
CN2018090004 2018-06-05
CNPCT/CN2018/090004 2018-06-05
EP18193916 2018-09-12
EP18193916.6 2018-09-12
CN2019086019 2019-05-08
CNPCT/CN2019/086019 2019-05-08
PCT/EP2019/064323 WO2019233941A1 (en) 2018-06-05 2019-06-03 Tetrahydro-1 h-pyrazino[2,1 -ajisoindolylquinoline compounds for the treatment of autoimmune disease

Publications (3)

Publication Number Publication Date
JP2021527041A JP2021527041A (ja) 2021-10-11
JP2021527041A5 true JP2021527041A5 (cg-RX-API-DMAC10.html) 2023-07-11
JP7374130B2 JP7374130B2 (ja) 2023-11-06

Family

ID=66793968

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020567772A Active JP7374130B2 (ja) 2018-06-05 2019-06-03 自己免疫疾患治療用の新規なテトラヒドロ-1H-ピラジノ[2,1-a]イソインドリルキノリン化合物

Country Status (19)

Country Link
US (1) US12157746B2 (cg-RX-API-DMAC10.html)
EP (1) EP3802539B1 (cg-RX-API-DMAC10.html)
JP (1) JP7374130B2 (cg-RX-API-DMAC10.html)
KR (1) KR20210018818A (cg-RX-API-DMAC10.html)
CN (1) CN112204028B (cg-RX-API-DMAC10.html)
AU (1) AU2019280728A1 (cg-RX-API-DMAC10.html)
BR (1) BR112020024782A2 (cg-RX-API-DMAC10.html)
CA (1) CA3098291A1 (cg-RX-API-DMAC10.html)
CL (1) CL2020003065A1 (cg-RX-API-DMAC10.html)
CO (1) CO2020014677A2 (cg-RX-API-DMAC10.html)
CR (1) CR20200584A (cg-RX-API-DMAC10.html)
IL (1) IL279144A (cg-RX-API-DMAC10.html)
MA (1) MA52747A (cg-RX-API-DMAC10.html)
MX (1) MX2020012827A (cg-RX-API-DMAC10.html)
PE (1) PE20210131A1 (cg-RX-API-DMAC10.html)
PH (1) PH12020552092A1 (cg-RX-API-DMAC10.html)
SG (1) SG11202011137SA (cg-RX-API-DMAC10.html)
TW (1) TW202016111A (cg-RX-API-DMAC10.html)
WO (1) WO2019233941A1 (cg-RX-API-DMAC10.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114599652B (zh) 2019-10-31 2024-07-12 豪夫迈·罗氏有限公司 用于治疗自身免疫性疾病的氢吡嗪并[1,2-d][1,4]二氮杂䓬化合物
WO2021094301A1 (en) * 2019-11-12 2021-05-20 F. Hoffmann-La Roche Ag Hydropyrazino[1,2-b]isoquinoline compounds for the treatment of autoimmune disease
EP4061816A1 (en) * 2019-11-19 2022-09-28 F. Hoffmann-La Roche AG Hydro-1h-pyrrolo[1,2-a]pyrazine compounds for the treatment of autoimmune disease
US12503471B2 (en) 2019-11-19 2025-12-23 Hoffmann-La Roche Inc. Triazatricycle compounds for the treatment of autoimmune disease
CN114761406B (zh) 2019-12-03 2024-04-19 豪夫迈·罗氏有限公司 用于治疗自身免疫性疾病的氢吡啶并[1,2-a]吡嗪化合物
JP2023533807A (ja) 2020-07-14 2023-08-04 エフ. ホフマン-ラ ロシュ アーゲー 自己免疫疾患の処置のためのヒドロイソキノリン又はヒドロナフチリジン化合物
WO2022022489A1 (zh) * 2020-07-27 2022-02-03 江苏恒瑞医药股份有限公司 吲哚稠环类衍生物、其制备方法及其在医药上的应用
CN114057759B (zh) * 2020-08-07 2023-05-16 江苏恒瑞医药股份有限公司 稠合四环类衍生物、其制备方法及其在医药上的应用
EP4253387A4 (en) * 2020-11-26 2024-05-15 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Fused tricyclic compound, preparation method therefor and application thereof in medicine
WO2023025109A1 (zh) * 2021-08-23 2023-03-02 上海维申医药有限公司 一类Toll样受体抑制剂及其制备和应用
CN114656363A (zh) * 2022-03-28 2022-06-24 南京林业大学 一种钯催化芳香酯类化合物的合成方法

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4273773A (en) 1979-09-24 1981-06-16 American Home Products Corporation Antihypertensive tricyclic isoindole derivatives
CA2551178C (en) 2003-12-24 2012-11-06 Biota Scientific Management Pty Ltd Polycyclic agents for the treatment of respiratory syncytial virus infections
WO2011106276A1 (en) 2010-02-25 2011-09-01 Merck Sharp & Dohme Corp. Task channel antagonists
UA117586C2 (uk) 2013-05-24 2018-08-27 ЯНССЕН САЙЄНСІЗ АЙРЛЕНД ЮСі Похідні піридину для лікування вірусних інфекцій та інших захворювань
KR101823488B1 (ko) 2013-10-14 2018-01-30 에자이 알앤드디 매니지먼트 가부시키가이샤 선택적으로 치환된 퀴놀린 화합물
ES2670550T3 (es) 2013-10-14 2018-05-30 Eisai R&D Management Co., Ltd. Derivados de quinolina selectivamente sustituidos
MX2021006804A (es) 2015-12-17 2023-01-13 Merck Patent Gmbh Antagonistas policiclicos del receptor 7/8 tipo toll (tlr7/8) y uso de los mismos en el tratamiento de trastornos inmunitarios.
US10071079B2 (en) 2016-06-29 2018-09-11 Bristol-Myers Squibb Company [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds
CN109715617B (zh) 2016-07-30 2022-04-19 百时美施贵宝公司 作为tlr7、tlr8或tlr9抑制剂的二甲氧基苯基取代的吲哚化合物
AU2017311047B2 (en) 2016-08-08 2021-07-22 Merck Patent Gmbh TLR7/8 antagonists and uses thereof
ES2902504T3 (es) 2016-09-09 2022-03-28 Bristol Myers Squibb Co Compuestos de indol sustituidos con piridilo
EP4059934B1 (en) 2016-09-09 2026-07-29 Novartis AG Compounds and compositions as inhibitors of endosomal toll-like receptors
WO2019018354A1 (en) 2017-07-18 2019-01-24 Merck Patent Gmbh ANTAGONISTS OF TLR7 / 8 AND USES THEREOF
CN110997670B (zh) 2017-08-04 2022-11-01 百时美施贵宝公司 [1,2,4]三唑并[4,3-a]吡啶基取代的吲哚化合物
EP3661926B1 (en) 2017-08-04 2022-02-23 Bristol-Myers Squibb Company Substituted indole compounds useful as inhibitors of tlr7/8/9
SG10202111648YA (en) 2017-10-05 2021-11-29 Glaxosmithkline Ip Dev Ltd Chemical compounds
CN111448190B (zh) 2017-11-14 2023-09-26 百时美施贵宝公司 取代的吲哚化合物
US12030878B2 (en) 2017-12-15 2024-07-09 Bristol-Myers Squibb Company Substituted indole ether compounds
MX2020006168A (es) 2017-12-18 2020-08-13 Bristol Myers Squibb Co Compuestos de 4-azaindol.
EA202091474A1 (ru) 2017-12-19 2020-11-18 Бристол-Маерс Сквибб Компани Замещенные индольные соединения, применимые в качестве ингибиторов tlr
EP3728253B1 (en) 2017-12-19 2024-03-27 Bristol-Myers Squibb Company 6-azaindole compounds
JP2021506862A (ja) 2017-12-19 2021-02-22 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung Tlr7/8アンタゴニストおよびそれらの使用
WO2019126081A1 (en) 2017-12-19 2019-06-27 Bristol-Myers Squibb Company Amide substituted indole compounds useful as tlr inhibitors
EA202091530A1 (ru) 2017-12-20 2020-09-14 Бристол-Маерс Сквибб Компани Диазаиндольные соединения
JP7287967B2 (ja) 2017-12-20 2023-06-06 ブリストル-マイヤーズ スクイブ カンパニー Tlr阻害剤として有効なアミノインドール化合物
KR102730859B1 (ko) 2017-12-20 2024-11-15 브리스톨-마이어스 스큅 컴퍼니 아릴 및 헤테로아릴 치환된 인돌 화합물
JP2021507889A (ja) 2017-12-22 2021-02-25 ノバルティス アーゲー ピラゾロピペリジン誘導体の新規な使用
WO2019220390A1 (en) 2018-05-18 2019-11-21 Novartis Ag Crystalline forms of a tlr7/tlr8 inhibitor
US11166942B2 (en) 2018-06-05 2021-11-09 Praxis Biotech LLC Inhibitors of integrated stress response pathway
TWI825144B (zh) 2018-08-10 2023-12-11 美商思達利醫藥公司 第二型轉麩醯胺酸酶(tg2)抑制劑
WO2021094301A1 (en) 2019-11-12 2021-05-20 F. Hoffmann-La Roche Ag Hydropyrazino[1,2-b]isoquinoline compounds for the treatment of autoimmune disease
US12503471B2 (en) 2019-11-19 2025-12-23 Hoffmann-La Roche Inc. Triazatricycle compounds for the treatment of autoimmune disease
US20230041743A1 (en) 2019-11-26 2023-02-09 Hoffmann-La Roche Inc. 1,8-naphthyridin-2-one compounds for the treatment of autoimmune disease

Similar Documents

Publication Publication Date Title
TWI854989B (zh) 用於抑制shp2活性之雜雙環化合物
AU2023201522B2 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
JP2022504936A5 (cg-RX-API-DMAC10.html)
CN105294683B (zh) Cdk类小分子抑制剂的化合物及其用途
JP2022527588A5 (cg-RX-API-DMAC10.html)
JP7374130B2 (ja) 自己免疫疾患治療用の新規なテトラヒドロ-1H-ピラジノ[2,1-a]イソインドリルキノリン化合物
CN101528225B (zh) 作为5ht3调节剂的2-氨基苯并噁唑羧酰胺
JP7511097B1 (ja) Her2変異阻害薬
JP2017524702A (ja) CDK阻害剤としての2−アミノ−ピリド[2,3−d]ピリミジン−7(8H)−オン誘導体及びその使用
CN112313228A (zh) 用于治疗自身免疫性疾病的新型杂芳基杂环基化合物
JP2017531672A5 (cg-RX-API-DMAC10.html)
US20200079763A1 (en) Quinoxaline and pyridopyrazine derivatives as a pi3kb inhibitors
HRP20241617T1 (hr) Piridazinilni amino-derivati kao inhibitori alk5
WO2013117645A1 (en) Imidazo [4, 5 -c] pyridine derivatives useful for the treatment of degenerative and inflammatory diseases
EP4061821A1 (en) Spiro(isobenzofuranazetidine) compounds for the treatment of autoimmune disease
JP2023533807A5 (cg-RX-API-DMAC10.html)
TW201940473A (zh) 作為多激酶抑制劑的胺基碳酸鹽及尿素化合物
EP3623369B1 (en) Novel morpholinyl amine compounds for the treatment of autoimmune disease
JP2023503165A (ja) 自己免疫疾患の処置のための1,8-ナフチリジン-2-オン化合物
JP2024089651A (ja) Her2変異阻害薬
RU2020142969A (ru) СОЕДИНЕНИЯ ТЕТРАГИДРО-1Н-ПИРАЗИНО[2,1- a]ИЗОИНДОЛИЛХИНОЛИНА ДЛЯ ЛЕЧЕНИЯ АУТОИММУННОГО ЗАБОЛЕВАНИЯ
RU2021131710A (ru) Соединения гексагидро-1h-пиразино[1,2-a]пиразина для лечения аутоиммунного заболевания
US20260085077A1 (en) Heterocyclic derivatives as janus kinase inhibitors
HK40111612A (en) Her2 mutation inhibitors
WO2025104123A1 (en) Heterocyclic derivatives as janus kinase inhibitors